Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy

Cell Commun Signal. 2023 Mar 14;21(1):61. doi: 10.1186/s12964-023-01077-5.

Abstract

Doxorubicin (DOX) is a powerful and commonly used chemotherapeutic drug, used alone or in combination in a variety of cancers, while it has been found to cause serious cardiac side effects in clinical application. More and more researchers are trying to explore the molecular mechanisms of DOX-induced cardiomyopathy (DIC), in which oxidative stress and inflammation are considered to play a significant role. This review summarizes signaling pathways related to oxidative stress and inflammation in DIC and compounds that exert cardioprotective effects by acting on relevant signaling pathways, including the role of Nrf2/Keap1/ARE, Sirt1/p66Shc, Sirt1/PPAR/PGC-1α signaling pathways and NOS, NOX, Fe2+ signaling in oxidative stress, as well as the role of NLRP3/caspase-1/GSDMD, HMGB1/TLR4/MAPKs/NF-κB, mTOR/TFEB/NF-κB pathways in DOX-induced inflammation. Hence, we attempt to explain the mechanisms of DIC in terms of oxidative stress and inflammation, and to provide a theoretical basis or new idea for further drug research on reducing DIC. Video Abstract.

Keywords: Cardiomyopathy; Doxorubicin; Inflammation; NF-κB; Nrf2; Oxidative stress; Signaling pathway.

Publication types

  • Video-Audio Media
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiomyopathies* / chemically induced
  • Doxorubicin / adverse effects
  • Humans
  • Inflammation / chemically induced
  • Kelch-Like ECH-Associated Protein 1 / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • NF-kappa B* / metabolism
  • Oxidative Stress
  • Signal Transduction
  • Sirtuin 1 / metabolism
  • Src Homology 2 Domain-Containing, Transforming Protein 1 / metabolism

Substances

  • SHC1 protein, human
  • Src Homology 2 Domain-Containing, Transforming Protein 1
  • NF-kappa B
  • Sirtuin 1
  • Kelch-Like ECH-Associated Protein 1
  • NF-E2-Related Factor 2
  • Doxorubicin